For vision-threatening diseases, such as diabetic macular edema (DME) understanding the economic value of treatments can help identify the direct and indirect benefits of different treatments, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
For vision-threatening diseases, understanding the economic value of treatments can help identify the direct and indirect benefits of different treatments, said Paul Hahn, MD, vitreoretinal surgeon at NJRetina.
Transcript
Which therapies are you looking at to better understand the economic value of treatments for diabetic macular edema (DME)?
Treatment of DME can involve observation, and it can involve interventions such as, most commonly, intravitreal anti-VEGF [vascular endothelial growth factor] therapy; steroids, such as intravitreal or periocular steroids; or focal laser treatment. In this project, we looked at the impact of all treatments combined to learn the economic impact of treatment of DME. But of course, the biggest impact is contributed by anti-VEGF therapy, which is the most commonly performed treatment for this condition.
With the population aging and the prevalence of diabetes increasing, what is the importance of understanding the economic value of treatments for diabetic macular edema?
As a retina specialist, we all understand very well how important it is to save someone's vision. And for the patient who's losing vision, they all understand that very well, also. But for most of us who don't have vision problems, we take our vision for granted, and that includes people who make decisions as to where resources are being allocated. It's important to understand the economic value of treatment of diabetic macular edema and other vision-threatening diseases to be able to place that in context and objectively understand how much value is created.
So, in this project, we looked at both the value of treatment of DME at an individual level and scaled that up to a national level. At an individual level, for example, we find increases in direct benefits and indirect benefit. Direct benefits meaning things like life expectancy, quality of life, and indirect benefits being disability, employment, and so forth. We find benefits for both. In fact, if we look at a hypothetical 51-year-old in our model, we find that the value of treatment of DME in that typical 51-year-old is equivalent to modelled value seen in other published reports of elimination of chronic disease or of immunotherapy for non–small cell lung cancer, a revolutionary treatment. It really highlights the importance of treatment of DME at an individual level.
If we scale that up to society, and if we look at the US population of DME, we see about $5.5 billion of direct and indirect benefits over 2 years, and that increases to almost $70 billion over 20 years. Again, just highlighting the importance of treatment of these vision-threatening diseases. In this era where health care resources are increasingly limited, I think understanding the economic value of treatment of diabetic macular edema is important to place that in context and really support the value for this.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Posters Detail Effects—and Uncertainty—of Drug Pricing Negotiations
May 7th 2024Research into the Inflation Reduction Act evaluated payer concerns, patient and physician behavior, which patients will benefit from the first 10 drugs selected for price negotiation, and the ripple effect into Medicaid at the state level.
Read More